ESR2 and breast carcinoma: As a transcriptional regulator through ER-α and ER-β, the extracellular application of E2 significantly increased the amplitude of Nav1.5 expression above the reference level in a dose-dependent manner in MDA-MB-231 breast cancer cells, leading to a decrease in cellular adhesiveness [29].